Prelude Therapeutics Incorporated (PRLD) Earnings
Prelude Therapeutics Incorporated is expected to report next earnings on November 11, 2026 (in NaN days), with a consensus EPS estimate of $-0.16. PRLD has beaten EPS estimates in 9 of its last 12 reported quarters (average surprise -115.1% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 11, 2026 | $-0.20 | $-0.14 | +28.8% | $6M | +0.0% |
| May 12, 2026 | $-0.27 | $-0.13 | +51.9% | $5M | +0.0% |
| Mar 10, 2026 | $-0.03 | $-0.20 | -566.7% | $6M | -72.5% |
| Nov 12, 2025 | $-0.35 | $-0.26 | +25.7% | $7M | -68.3% |
| Aug 14, 2025 | $-0.45 | $-0.41 | +8.9% | — | — |
| Mar 10, 2025 | $-0.49 | $-0.38 | +22.4% | $4M | — |
| Feb 15, 2024 | $-0.50 | $-0.47 | +6.0% | $3M | — |
| Nov 1, 2023 | $-0.58 | $-0.45 | +22.4% | — | — |
| Aug 3, 2023 | $-0.65 | $-0.54 | +16.9% | — | — |
| Mar 15, 2023 | $-0.63 | $-0.60 | +4.8% | — | — |
| Nov 14, 2022 | $-0.63 | $-0.63 | +0.0% | — | — |
| Mar 16, 2022 | $-0.69 | $-0.71 | -2.9% | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q4 FY2025 · March 10, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Discussed aspects such as the clinical development plan for molecule 396 including a parallel design in myelofibrosis and polycythemia vera with input from key opinion leaders, the rationale behind choosing a degrader approach for CAT6 including selectivity and efficacy advantages, and work on the mutant Cal-R degrader with differentiation points like potency and potential for subcutaneous administration.
Guidance
Cash position was $106 million in cash, which takes the company into the second quarter of 2027, and this does not account for the potential $100 million option payment from Insight.
Segment performance
Not explicitly mentioned in detail
Risks & headwinds
Not discussed in detail
Analyst Q&A
Q: Can you differentiate your molecule from other competitors and why Insight would partner with you?
A: Discussed selectivity profile, learnings from clinic/preclinical stages, and parallel clinical development plan.
Q: Talk about the clinical development plan for molecule 396?
A: Parallel design in myelofibrosis and polycythemia vera, enrolling the right patients and getting FDA approval for the parallel approach.
Q: Talk about the CAT6 degrader?
A: Differentiated by degrader approach for better selectivity and efficacy, plan to file IND by mid - year.
Q: What is the cash position?
A: $106 million in cash, lasting into the second quarter of 2027